Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells

Rieger,Christiane; Huebner,Doreen; Temme,Achim; Wirth,Manfred  P.; Fuessel,Susanne

doi:10.3892/ijo.2015.3096

Antisense- and siRNA-mediated inhibition of the anti-apoptotic gene Bcl-xL for chemosensitization of bladder cancer cells

Authors:
- Christiane Rieger
- Doreen Huebner
- Achim Temme
- Manfred P. Wirth
- Susanne Fuessel
View Affiliations

Affiliations: Department of Urology, Technische Universität Dresden, D-01307 Dresden, Germany, Department of Neurosurgery, Technische Universität Dresden, D-01307 Dresden, Germany
Published online on: July 20, 2015 https://doi.org/10.3892/ijo.2015.3096
Pages: 1121-1130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bcl-xL is an apoptosis inhibitor that is upregulated in bladder cancer (BCa) and provides an attractive target for molecular therapies. Treatment with specific antisense oligodeoxynucleotides (AS‑ODNs) or small interfering RNAs (siRNAs) were able to sensitize BCa cells to conventional chemotherapeutics. Ten new Bcl‑xL‑targeting AS‑ODNs were systematically designed by using predicting software. AS‑BX2034 and AS‑BX2100 as well as the previously optimized siRNA construct si‑BX713 were selected for further detailed in vitro analysis in the BCa cell lines UM‑UC‑3 and EJ28. Bcl‑xL mRNA and protein expression levels, cell viability and apoptosis were examined 72 h after transfection. A single treatment with AS‑BX2034 or AS‑BX2100 caused only a low inhibition of the Bcl‑xL mRNA expression with the highest reduction of ≤20% in UM‑UC‑3 cells. In contrast, a single treatment with si‑BX713 strongly decreased Bcl‑xL mRNA expression level by ≤69% in UM‑UC‑3 cells and by ≤86% in EJ28 cells. Both gene expression inhibitor types induced a low to moderate reduction of viability. Depending on the cell line, a combined treatment with AS‑BX2100 or si‑BX713 and cisplatin (CDDP) caused an additional inhibition of cell viability by ~33 and 38%, respectively, compared to the respective control construct combined with CDDP. In comparison to the respective control treatment, combinations of AS‑BX2100 and CDDP led to a stronger induction of apoptosis by 57% in UM‑UC‑3 cells and 44% in EJ28 cells, whereas the combination of si‑BX713 and CDDP enhanced apoptosis by 38 and 118% in UM‑UC‑3 and EJ28 cells, respectively. Our comparative studies showed a stronger knockdown of Bcl‑xL by the siRNA construct compared to AS‑ODN treatment in both BCa cell lines. In combinatory treatments, the Bcl‑xL-directed siRNA markedly enhanced the anti-proliferative and apoptotic effects of CDDP and therefore, may serve as suitable tool for chemosensitization of BCa cells.

View Figures

View References

1	Luo J, Solimini NL and Elledge SJ: Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI
2	Czabotar PE, Lessene G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 15:49–63. 2014. View Article : Google Scholar
3	Yu X, Yang L, Cairns MJ, Dass C, Saravolac E, Li X and Sun LQ: Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme. Oncotarget. 5:9039–9048. 2014.PubMed/NCBI
4	Gazzaniga P, Gradilone A, Silvestri I, Gandini O, Giuliani L, Vincenzoni A, Gallucci M, Frati L and Agliano AM: Variable levels of bcl-2, bcl-x and bax mRNA in bladder cancer progression. Oncol Rep. 5:901–904. 1998.PubMed/NCBI
5	Giménez-Bonafé P, Tortosa A and Pérez-Tomás R: Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets. 9:320–340. 2009. View Article : Google Scholar : PubMed/NCBI
6	Youssef RF and Lotan Y: Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. Sci World J. 11:369–381. 2011. View Article : Google Scholar
7	Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A: European Association of Urology: EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
8	Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, et al: European Association of Urology: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
9	Duggan BJ, Gray S, Johnston SR, Williamson K, Miyaki H and Gleave M: The role of antisense oligonucleotides in the treatment of bladder cancer. Urol Res. 30:137–147. 2002. View Article : Google Scholar : PubMed/NCBI
10	Yoshimine S, Kikuchi E, Kosaka T, Mikami S, Miyajima A, Okada Y and Oya M: Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma. Br J Cancer. 108:2312–2320. 2013. View Article : Google Scholar : PubMed/NCBI
11	Lebedeva I, Raffo A, Rando R, Ojwang J, Cossum P and Stein CA: Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol. 166:461–469. 2001. View Article : Google Scholar : PubMed/NCBI
12	Achenbach TV, Brunner B and Heermeier K: Oligonucleotide-based knockdown technologies: Antisense versus RNA interference. Chem Biochem. 4:928–935. 2003.
13	Scherer LJ and Rossi JJ: Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol. 21:1457–1465. 2003. View Article : Google Scholar : PubMed/NCBI
14	Bolenz C, Becker A, Trojan L, Schaaf A, Cao Y, Weiss C, Alken P and Michel MS: Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. Urol Oncol. 25:476–482. 2007. View Article : Google Scholar : PubMed/NCBI
15	Littlejohn JE, Cao X, Miller SD, Ozvaran MK, Jupiter D, Zhang L, Rodarte C and Smythe WR: Bcl-xL antisense oligo-nucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. Int J Cancer. 123:202–208. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kunze D, Erdmann K, Froehner M, Wirth MP and Fuessel S: siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells. Anticancer Res. 32:4313–4318. 2012.PubMed/NCBI
17	Bolenz C, Weiss C, Wenzel M, Gabriel U, Steidler A, Becker A, Herrmann E, Trojan L and Michel MS: In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma. J Cancer Res Clin Oncol. 135:679–686. 2009. View Article : Google Scholar
18	Gabriel U, Bolenz C, Becker A, Schaaf A, Steidler A, Trojan L, Weiss C and Michel MS: Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma. Oncol Rep. 20:1419–1423. 2008.PubMed/NCBI
19	Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP and Meye A: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res. 9:3794–3800. 2003.PubMed/NCBI
20	Kirsh EJ, Baunoch DA and Stadler WM: Expression of bcl-2 and bcl-X in bladder cancer. J Urol. 159:1348–1353. 1998. View Article : Google Scholar : PubMed/NCBI
21	Kunze D, Wuttig D, Fuessel S, Kraemer K, Kotzsch M, Meye A, Grimm MO, Hakenberg OW and Wirth MP: Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells. Anticancer Res. 28B:2259–2263. 2008.
22	Chan JH, Lim S and Wong WS: Antisense oligonucleotides: From design to therapeutic application. Clin Exp Pharmacol Physiol. 33:533–540. 2006. View Article : Google Scholar : PubMed/NCBI
23	Lebedeva I, Rando R, Ojwang J, Cossum P and Stein CA: Bcl-xL in prostate cancer cells: Effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 60:6052–6060. 2000.PubMed/NCBI
24	Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP and Meye A: Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxy-nucleotides and siRNA. Cancer Lett. 232:243–254. 2006. View Article : Google Scholar : PubMed/NCBI
25	Miyagishi M, Hayashi M and Taira K: Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
26	Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A and Malvy C: Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 296:1000–1004. 2002. View Article : Google Scholar : PubMed/NCBI
27	Kretschmer-Kazemi Far R and Sczakiel G: The activity of siRNA in mammalian cells is related to structural target accessibility: A comparison with antisense oligonucleotides. Nucleic Acids Res. 31:4417–4424. 2003. View Article : Google Scholar : PubMed/NCBI